Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 1, 2013, Pages

  Guan, Yongjun ^a   Pazgier, Marzena ^a   Sajadi, Mohammad M ^a   Kamin Lewis, Roberta ^a   Al Darmarki, Salma ^a   Flinko, Robin ^a   Lovo, Elena ^a   Wu, Xueji ^a   Robinson, James E ^b   Seaman, Michael S ^c   Fouts, Timothy R ^d   Gallo, Robert C ^a   DeVico, Anthony L ^a   Lewis, George K ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Profectus BioSciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN 41; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANTIBODY SPECIFICITY; ARTICLE; EFFECTOR CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; VIRUS ENTRY;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD4; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MODELS, MOLECULAR; NEUTRALIZATION TESTS; PROTEIN CONFORMATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84871960572     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1217609110     Document Type: Article

References (92)

1. Li A, et al. (1997) Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res Hum Retroviruses 13(8):647-656. (Pubitemid 27210453)
2. Mascola JR, et al. (1997) Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J Virol 71(10):7198-7206. (Pubitemid 27391653)
3. Mascola JR, et al. (1999) Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73(5):4009-4018. (Pubitemid 29189846)
4. Baba TW, et al. (2000) Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6(2):200-206. (Pubitemid 30082366)
5. Parren PW, et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75(17):8340-8347. (Pubitemid 32743706)
6. Nishimura Y, et al. (2002) Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 76(5):2123-2130. (Pubitemid 34150679)
7. Walker LM, Burton DR (2010) Rational antibody-based HIV-1 vaccine design: Current approaches and future directions. Curr Opin Immunol 22(3):358-366.
8. Baum LL, et al. (1996) HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 157(5):2168-2173. (Pubitemid 126449697)
9. Forthal DN, et al. (1999) Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis 180(4):1338-1341. (Pubitemid 30070224)
10. Ljunggren K, et al. (1990) Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis 161(2):198-202. (Pubitemid 20056646)
11. Forthal DN, et al. (2007) FcgammaRIIa genotype predicts progression of HIV infection. J Immunol 179(11):7916-7923.
12. Chung AW, et al. (2011) Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci USA 108(18):7505-7510.
13. Chung AW, et al. (2011) Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol 24(2):171-175.
14. Chung AW, et al. (2011) Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr 58(2):127-131.
15. Banks ND, Kinsey N, Clements J, Hildreth JE (2002) Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 18(16):1197-1205. (Pubitemid 35370608)
16. Sun Y, et al. (2011) Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J Virol 85(14):6906-6912.
17. Forthal DN, Landucci G (1998) In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. J Immunol Methods 220(1-2):129-138. (Pubitemid 28527075)
18. Gómez-Román VR, et al. (2005) Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 174(4):2185-2189. (Pubitemid 40223963)
19. Florese RH, et al. (2009) Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 182(6):3718-3727.
20. Hidajat R, et al. (2009) Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 83(2):791-801.
21. Xiao P, et al. (2010) Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 84(14):7161-7173.
22. Forthal DN, Gilbert PB, Landucci G, Phan T (2007) Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 178(10):6596-6603. (Pubitemid 46717444)
23. Haynes BF, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366(14):1275-1286.
24. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J (2012) HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 8(6):e1002739.
25. Hessell AJ, et al. (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158):101-104. (Pubitemid 47373775)
26. Hessell AJ, et al. (2009) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15(8):951-954.
27. Nishimura Y, et al. (2003) Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: Implications for HIV-1 vaccine development. Proc Natl Acad Sci USA 100(25):15131-15136. (Pubitemid 37518028)
28. Lewis GK (2010) Challenges of antibody-mediated protection against HIV-1. Expert Rev Vaccines 9(7):683-687.
29. Scott CF, Jr., et al. (1990) Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain. Proc Natl Acad Sci USA 87(21):8597-8601.
30. Koup RA, et al. (1991) Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS 5(11):1309-1314.
31. Ferrari G, et al. (2011) A HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent ADCC activity and defines a common ADCC epitope in human hiv-1 serum. Journal of Virology 85(14):7029-7036.
32. Tyler DS, et al. (1990) Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol 145(10):3276-3282.
33. Robinson JE, Yoshiyama H, Holton D, Elliott S, Ho DD (1992) Distinct antigenic sites on HIV gp120 identified by a panel of human monoclonal antibodies. abstr. Q449. J Cell Biochem Suppl 16E:71.
34. Thali M, et al. (1993) Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67(7):3978-3988. (Pubitemid 23180722)
35. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE (2002) Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res Hum Retroviruses 18(16):1207-1217. (Pubitemid 35370609)
36. Decker JM, et al. (2005) Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201(9):1407-1419. (Pubitemid 40664085)
37. Moore JP, et al. (1994) Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 68(12):8350-8364. (Pubitemid 24362729)
38. Pancera M, et al. (2010) Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci USA 107(3):1166-1171.
39. Moore JP, Willey RL, Lewis GK, Robinson J, Sodroski J (1994) Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J Virol 68(11):6836-6847. (Pubitemid 24328732)
40. Xiang SH, et al. (2003) Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology 315(1):124-134.
41. Wyatt R, et al. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393(6686):705-711. (Pubitemid 28289663)
42. Lewis GK, et al. (2011) Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins. J Virol 85(24):13097-13104.
43. Sullivan N, et al. (1998) CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization. J Virol 72(6):4694-4703. (Pubitemid 28215644)
44. Moore JP, Sodroski J (1996) Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 70(3):1863-1872. (Pubitemid 26062950)
45. Finzi A, et al. (2010) Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell 37(5):656-667.
46. Wyatt R, et al. (1997) Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. J Virol 71(12):9722-9731. (Pubitemid 27492421)
47. Sela M, Mozes E (1966) Dependence of the chemical nature of antibodies on the net electrical charge of antigens. Proc Natl Acad Sci USA 55(2):445-452.
48. Huang CC, et al. (2004) Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci USA 101(9):2706-2711.
49. Moulard M, et al. (2002) Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci USA 99(10):6913-6918. (Pubitemid 34526232)
50. Zhang MY, et al. (2004) Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J Mol Biol 335(1):209-219.
51. Chothia C, Lesk AM (1987) Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196(4):901-917. (Pubitemid 17127946)
52. Dey B, et al. (2009) Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog 5(5):e1000445.
53. Huang CC, et al. (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310(5750):1025-1028.
54. Rossio JL, et al. (1998) Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 72(10):7992-8001. (Pubitemid 28421792)
55. DeVico AL (2007) CD4-induced epitopes in the HIV envelope glycoprotein, gp120. Curr HIV Res 5(6):561-571.
56. Kwong PD, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393(6686):648-659. (Pubitemid 28289647)
57. Finnegan CM, Berg W, Lewis GK, DeVico AL (2001) Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion. J Virol 75(22):11096-11105. (Pubitemid 33031576)
58. Finnegan CM, Berg W, Lewis GK, DeVico AL (2002) Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J Virol 76(23):12123-12134. (Pubitemid 35304311)
59. Labrijn AF, et al. (2003) Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77(19):10557-10565. (Pubitemid 37129699)
60. Zhang MY, et al. (2003) Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods 283(1-2):17-25.
61. Scheid JF, et al. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458(7238):636-640.
62. Darbha R, et al. (2004) Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry 43(6):1410-1417. (Pubitemid 38200545)
63. Huang CC, et al. (2007) Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317(5846):1930-1934.
64. Gnanakaran S, et al. (2010) Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLOS Comput Biol 6(10):e1000955.
65. Klein F, et al. (2012) Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med 209(8):1469-1479.
66. Bonsignori M, et al. (2012) ADCC-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. Journal of Virology 85(14):11521-11532.
67. Sajadi MM, Heredia A, Le N, Constantine NT, Redfield RR (2007) HIV-1 natural viral suppressors: Control of viral replication in the absence of therapy. AIDS 21(4):517-519.
68. Guan Y, et al. (2009) Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci USA 106(10):3952-3957.
69. Sajadi MM, et al. (2009) Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J Acquir Immune Defic Syndr 50(4):403-408.
70. Sajadi M, Redfield RR (2010) Long-term nonprogressive disease among individuals with untreated HIV infection. JAMA 304(16):1784-1785, author reply 1785-1786.
71. Sajadi MM, et al. (2011) Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J Acquir Immune Defic Syndr 57(1):9-15.
72. Sanders RW, et al. (2002) Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76(17):8875-8889. (Pubitemid 34864082)
73. Iyer SP, et al. (2007) Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers. AIDS Res Hum Retroviruses 23(6):817-828. (Pubitemid 47047922)
74. Fouts TR, et al. (2000) Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J Virol 74(24):11427-11436. (Pubitemid 32222289)
75. Wyatt R, et al. (1995) Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 69(9):5723-5733.
76. Walker LM, et al.; Protocol G Principal Investigators (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326(5950):285-289.
77. Roben P, et al. (1994) Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 68(8):4821-4828. (Pubitemid 24226546)
78. Moore JP, Wallace LA, Follett EA, McKeating JA (1989) An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS 3(3):155-163. (Pubitemid 19111442)
79. DeVico A, et al. (2007) Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci USA 104(44):17477-17482. (Pubitemid 350219863)
80. Gómez-Román VR, et al. (2006) A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods 308(1-2):53-67. (Pubitemid 43107954)
81. O ' Doherty U, Swiggard WJ, Malim MH (2000) Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 74(21):10074-10080.
82. Chertova E, et al. (2002) Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 76(11):5315-5325. (Pubitemid 34517882)
83. Seaman MS, et al. (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84(3):1439-1452.
84. Otwinowski Z, Minor W, Charles W, Carter, Jr. (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods in Enzymology (Academic, New York) Vol 276, pp 307-326.
85. Keegan RM, Winn MD (2008) MrBUMP: An automated pipeline for molecular replacement. Acta Crystallogr D Biol Crystallogr 64(Pt 1):119-124. (Pubitemid 350308685)
86. McCoy AJ (2007) Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr D Biol Crystallogr 63(Pt 1):32-41.
87. Anonymous; Collaborative Computational Project, Number 4 (1994) The CCP4 suite: Programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50(Pt 5):760-763.
88. Yin J, Andryski SE, Beuscher AE IV, Stevens RC, Schultz PG (2003) Structural evidence for substrate strain in antibody catalysis. Proc Natl Acad Sci USA 100(3):856-861. (Pubitemid 36183920)
89. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53(Pt 3):240-255. (Pubitemid 27235885)
90. Afonine PV, et al. (2010) Joint X-ray and neutron refinement with phenix.refine. Acta Crystallogr D Biol Crystallogr 66(Pt 11):1153-1163.
91. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2126-2132.
92. Chen VB, et al. (2010) MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66(Pt 1):12-21.